DelMar Pharmaceuticals' Promising New Data Support the Potential of VAL-083 to Meet Significant Unmet Medical Needs in the Treatment of Glioblastoma Multiforme November 17, 2014 • 8:00 AM EST
DelMar Pharmaceuticals Presents Preclinical Data Supporting VAL-083 as a Potential New Treatment in Glioblastoma at the Society of Neuro-Oncology Annual Meeting November 14, 2014 • 11:45 AM EST
DelMar Pharmaceuticals Announces September 30, 2014 Results and Provides Corporate Update November 10, 2014 • 8:00 AM EST
DelMar Pharmaceuticals Invited to Present New Data on VAL-083 in the Treatment of Glioblastoma Multiforme at the Society for NeuroOncology Annual Meeting November 6, 2014 • 8:00 AM EST
VAL-083 Demonstrates Promise as a Potential Treatment for Non-small Cell Lung Cancer October 9, 2014 • 8:44 AM EDT
DelMar Pharmaceuticals Announces Presentations at Upcoming Scientific Meetings October 6, 2014 • 11:47 AM EDT
DelMar Pharmaceuticals to Present at the SeeThruEquity Fall Microcap Investor Conference September 4, 2014 • 8:00 AM EDT
DelMar Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent for VAL-083 September 3, 2014 • 8:00 AM EDT
DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments August 29, 2014 • 8:00 AM EDT
DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference August 27, 2014 • 2:57 PM EDT